StockData
Tenaya Therapeutics, Inc. logo

Tenaya Therapeutics, Inc. (TNYA) stock

TNYANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$0.31−0.02 (-4.93%)

Close on Nov 18, 2026Market cap $68.82MP/E –Yield –

Tenaya Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Tenaya Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$105.86M. For fiscal 2025 it was -$93.33M. The highest annual figure on record is -$38.91M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$93.33M–
FY2024Dec 31, 2024-$115.95M–
FY2023Dec 31, 2023-$131.19M–
FY2022Dec 31, 2022-$125.62M–
FY2021Dec 31, 2021-$72.81M–
FY2020Dec 31, 2020-$38.91M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$44.09M–
Q1 FY2026Mar 31, 2026-$20.07M–
Q4 FY2025Dec 31, 2025-$20.78M–
Q3 FY2025Sep 30, 2025-$20.94M–
Q2 FY2025Jun 30, 2025-$24.08M–
Q1 FY2025Mar 31, 2025-$27.54M–
Q4 FY2024Dec 31, 2024-$24.65M–
Q3 FY2024Sep 30, 2024-$26.71M–
Q2 FY2024Jun 30, 2024-$30.82M–
Q1 FY2024Mar 31, 2024-$33.76M–
Q4 FY2023Dec 31, 2023-$31.45M–
Q3 FY2023Sep 30, 2023-$30.92M–
Q2 FY2023Jun 30, 2023-$35.10M–
Q1 FY2023Mar 31, 2023-$33.72M–
Q4 FY2022Dec 31, 2022-$34.55M–
Q3 FY2022Sep 30, 2022-$31.30M–
Q2 FY2022Jun 30, 2022-$28.62M–
Q1 FY2022Mar 31, 2022-$31.15M–
Q4 FY2021Dec 31, 2021-$26.16M–
Q3 FY2021Sep 30, 2021-$18.30M–
Q2 FY2021Jun 30, 2021-$15.24M–
Q1 FY2021Mar 31, 2021-$13.11M–
Q4 FY2020Dec 31, 2020-$10.32M–
Q3 FY2020Sep 30, 2020-$10.45M–
Q2 FY2020Jun 30, 2020-$8.87M–

More Tenaya Therapeutics figures

See a number that looks wrong?